Lopes et al. observed overexpression of the ERK5 gene in pre-chemotherapy samples compared to post-treatment and normal bone specimens, associating high ERK5 expression with adverse therapeutic outcomes and lower survival rates in osteosarcoma patients [192]. The gene discussed is MAPK7; the disease is osteosarcoma.